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ABSTRACT  
Background: Lupus nephritis (LN) is a common manifestation of systemic lupus 
erythematosus (SLE) and is associated with end-stage renal disease, need for renal 
replacement therapy and death. There is no African data comparing the efficacy or outcome 
of patients managed with Mycophenolate mofetil (MMF) or intravenous (IV)  
cyclophosphamide (CYC) during induction of proliferative LN.  
Objectives: The study aimed to assess treatment response after induction therapy with MMF 
or IV CYC in patients with proliferative LN at a single centre in South Africa. 
Methods: We performed a retrospective review of records of patients with biopsy proven 
proliferative LN diagnosed and treated with either MMF or IV CYC at Groote Schuur Hospital 
(GSH), Cape Town, South Africa. We assessed remission status, adverse events and death 
between the two groups. 
Results:  Patients treated with IVCYC and MMF had a mean age of 30.3 ± 11.2 and 27.0 ± 6.9 
years respectively, (p=0.23). At baseline, the IVCYC group had significantly higher mean 
arterial pressure, serum creatinine and glomerular crescents (p<0.05). After completion of 
induction therapy, there was no significant difference in remission status (76.0% vs 87.5%, 
p=0.33) or relapse status (8.1% vs 10.3%; p=0.22) for the IVCYC and MMF groups, respectively. 
There was no significant difference in occurrence of infective complications IVCYC 20(30.8%) 
vs MMF 3(15.7%) p=0.20 or mortality IVCYC 14(21.5%) vs MMF 1(5.4%)  between both groups. 
Estimated GFR at baseline was the only predictor of death (1.0 [0.9 – 1.0]; p=0.001).  
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Conclusion: Our study shows similar outcomes following induction treatment with MMF or 
IVCYC in patients with biopsy proven proliferative LN in South Africa. However, a prospective 
and randomized study is needed to adequately compare these outcomes. 
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CHAPTER 1: LITERATURE REVIEW 
 
1.0 The Objectives of the literature review  
 To give a broad overview of what is known about Systemic Lupus 
Erythematosus (SLE) and lupus nephritis (LN) from published literature and 
international society guidelines.  
 To put into context what is already known about LN globally and from an 
African perspective. 
2.0 Broad overview of SLE  
2.1 Epidemiology  
Systemic lupus erythematosus (SLE) is the most common autoimmune disease, with peak 
incidence and prevalence reported to be about 23.2/100 000 person-years and 24/100 000 
people respectively(1). A multinational and multiracial study showed that the burden of SLE 
is significantly higher in non-Caucasian populations(2). More specifically, populations of 
African ancestry have the highest incidence of SLE, while Caucasians have the lowest. 
Furthermore, SLE is far more prevalent in females than males irrespective of age and ethnic 
groups(1). The ethnic difference also exists for SLE severity as African-American and Afro-
Caribbean’s in Europe and West Indies express the most serious forms of the disease(1).  SLE 
accounts for substantial morbidity, despite ongoing therapeutic advances, the mortality 
remains high as documented by the standardised mortality ratio of 2.66 found in the current 
meta-analysis of complete cause-specific mortality in SLE(3). The leading cause of this 
12 | P a g e  
 
increased mortality are infections, renal disease and cardiovascular diseases while the risk of 
death due to malignancy is not increased(4). 
In Sub-Saharan Africa (SSA), SLE was regarded as a rare condition until the 20th century (5). 
However, the conclusions from reviews were limited by small numbers of studies included. 
Daily clinical experience and ever-increasing growth of the African literature on SLE suggest 
that the idea of SLE scarcity is a myth. The seeming low incidence rate in Africa may be the 
result of underdiagnoses due to poor access to health care, low disease recognition within 
primary health care settings, inadequate access to diagnostic tools and inadequate numbers 
of specialist physicians(6).  
2.2 Clinical presentation 
Patients who have SLE often present in numerous ways and may go on undiagnosed for many 
years due to non-specific symptoms such as fever and malaise. 
Table 1: shows the various clinical presentations in a systematic review and meta-analysis of 
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Table 1: Prevalence of clinical features in patients with SLE(5) 
SLE manifestations  SLE in SSA, prevalence of clinical features (%) 
Rheumatology  5 – 99 
Dermatological 4 – 100 
Haematological  1 – 87 
Constitutional symptoms  6 – 79 
Renal 6 – 80 
Cardiovascular  2 – 46 
Serosal 6 – 31 
Neuropsychiatry 5 -47 
Pleuropulmonary  6 -25 
  
SLE – systemic lupus erythematosus; SSA – sub-Saharan Africa 
2.3 Diagnosis of SLE  
The diagnosis of SLE is based on a composite of clinical manifestations, as well as 
haematological, immunological and histological (mainly of the skin and kidneys) features. SLE 
is a complex challenging condition that presents exclusive issues in diagnosis and 
management. Patients present in many different ways and various clinical symptoms do not 
frequently occur concurrently and may ensue at any stage of the disease. Fever, fatigue and 
arthralgia are the most often occurring non-specific symptoms at disease onset. Additionally,  
joint swelling or a “butterfly” rash – predominantly in women of child bearing age should 
prompt consideration for SLE(7). 
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 SLE is diagnosed based on the Systematic Lupus International Collaborating Clinics (SLICC) 
criteria(8), which involves:  
1) Fulfilment of at least four criteria, with at least one clinical criterion and one immunological 
criterion.  
2) Lupus nephritis as the sole clinical criterion in the presence of anti-nuclear antibodies (ANA) 
or anti-double stranded (Anti-DsDNA) antibodies. 
Table 2: SLICC CRITERIA(8) 
“Clinical Features Immunological features 
1. Acute cutaneous lupus   ANA 
2. Chronic cutaneous lupus Anti- dsDNA 
3. Oral or nasal ulcers Antiphospholipid antibodies 
4. Arthritis Low complement ( C3, C4,CH50) 
5. Serositis Direct Coombs’ test (do not count in 
the presence of haemolytic anaemia) 
6. Non-scarring alopecia Anti-Sm antibodies 
7. Renal  
8. Neurological  
9. Haemolytic anaemia  
10. Leukopenia  
11. Thrombocytopenia”  
“ANA- antinuclear antibody, anti-dsDNA- anti-double-stranded deoxyribonucleic acid, Anti-
Sm – anti smith antibodies”.  
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3. Lupus nephritis
3.1 Definition of lupus nephritis 
Lupus nephritis (LN) should be considered in any SLE patient with impaired kidney function, 
proteinuria, hypertension or an active urine sediment according to the KDIGO guidelines(9). 
An active sediment includes presence of haematuria, leukocytes, red blood cell casts and 
white cell casts(9). Kidney involvement is specifically defined as persistent proteinuria 
(>0.5g/24h) or presence of cellular red cell casts by the SLICC criteria(8). However, LN must 
be confirmed by kidney biopsy because histological findings provide the basis for treatment 
recommendation(9).  
The clinical features of LN is often present in conjunction with other extra-renal 
manifestations of SLE, including joint pain, malar rash, oral ulcers and photosensitivity. A 
previous study from our centre found joint and skin involvement to commonly occur along 
with kidney involvement(10).  However, patients with LN will present with asymptomatic 
urinary involvement (mild proteinuria and/or haematuria alone),  nephritic syndrome 
(oliguria, minimal proteinuria, haematuria, hypertension and azotaemia) or with signs  of 
nephrotic syndrome (anasarca, heavy proteinuria, hypalbuminaemia)(11).  
Routine performance of urinalysis (dipstick and microscopic examination) offer the best 
chance  for early detection of LN (12).  
3.2 Burden of lupus Nephritis in Africa and globally 
LN is a common and major manifestation of SLE, occurring in 40-60% of SLE patients(13). LN 
is a huge contributing factor of morbidity and mortality in SLE patients. One study from South 
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African  has shown that over  half of 226 SLE patients from a lupus clinic had either died or 
been lost to follow up at 55 months from the time of diagnosis and kidney involvement (LN) 
was a major predictor of  mortality with a 5 year survival rate of 60%(14). 
LN is the commonest secondary cause of glomerular disease and a frequent cause of 
nephrotic range proteinuria globally (12). A systematic review on the prevalence of  
histologically proven glomerular diseases in Africa showed that LN was the most common 
reported both from North Africa and sub-Saharan Africa despite the high prevalence of HIV 
in the region(15). Up to 50% of SLE patients have derangements  of renal function or urine 
(proteinuria, haematuria or cellular cast) early on in the disease course, while approximately 
80% may later develop overt aberrations of the renal function(13). The prevalence of LN in 
the Euro-lupus cohort was 39 %(16), in South Africa the prevalence was slightly higher at 
43%(17).  
 
3.3 Lupus nephritis classification 
LN is classified using the International Society of Nephrology (ISN) / Renal Pathology Society 
(RPS) classification of lupus nephritis 2003. It allows standardisation of definitions and 
emphasizes clinically relevant lesions making it easier to compare between 
centres(18)(19)(20). It is worth stating that the classification of LN refers to only glomerular 
changes that are a result of immune complex deposition. Other features can still be found, 
including tubulointerstitial inflammation and vasculopathy or thrombotic microangiopathy 
(usually in association with antiphospholipid antibodies). The degree of tubulointerstitial 
scarring is also prognostic and should be documented(21). A minimum of 10 glomeruli is a 
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prerequisite to logically exclude focal disease and the biopsy should be examined by light 
microscopy, immunofluorescence and if feasible by electron microscopy(20). 
Table 3:  Abbreviated ISN/RPS Classification of lupus nephritis(18) 
Class I Minimal mesangial lupus nephritis  
Class II Mesangial proliferative lupus nephritis 
Class III Focal lupus nephritis (<50 involvement) 
Class IV Diffuse segmental or diffuse global lupus nephritis (≥50% involvement) 
Class V Membranous lupus nephritis 
Class VI Advanced sclerosing lupus nephritis 
The association between the histological class of LN and the clinical course of the disease is 
well documented. Patients with class II and class V (pure membranous LN)- non proliferative 
LN disease frequently have a slow decline in renal function over long periods of surveillance. 
In contrast, patients with class III and class IV (or those mixed with class V)- proliferative LN 
disease predominantly have a more aggressive course of disease(11).  
 In SSA there are limited studies on biopsy confirmed LN mostly due to lack of expertise in 
performing a renal biopsy and frequently the lack of pathology support for handling of tissue 
or reporting of histologies (22)(23). Worldwide, several studies show that proliferative classes 
of LN are more frequently encountered than non-proliferative types(24)(25)(26)(27)(28)(29). 
In a study of 251 patients assessing the clinocopathological features of LN in South Africa, 63% 
were shown to have  proliferative classes of LN(12).Factors that were related with 
proliferative LN were : “male gender, haematuria on dipstick, proteinuria, low serum albumin, 
low complement and a positive anti-DsDNA”(12). 
3.4 The Role of renal biopsies in lupus nephritis 
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Guidelines support performing a renal biopsy when there is suggestion of renal involvement, 
since clinical and laboratory features do not accurately predict the histological class.(30) 
 The criteria for suspicion of renal involvement includes(9)(31): 
 Unexplained decrease in renal function 
 Proteinuria of  > 500mg/day 
 Active urinary sediment (granular casts, white blood cell (WBC) casts, red blood cell 
(RBC) casts.  
 
4. TREATMENT OF LUPUS NEPHRITIS  
Treatment of LN is dictated by the class of disease and degree of activity and chronicity indices 
and the 2003 ISN/RPS classification of LN allows for standardization of treatment(18). 
4.1 Adjunctive therapies in Lupus Nephritis 
Adjunctive therapies are initiated during the induction phase of treatment, a few may need 
to be halted after completing this therapy, and others will need to be continued throughout 
the maintenance phase. 
Frequently recommended adjunctive therapies in LN include (30):  
 Antimalarials: chloroquine or hydroxychloroquine is advocated for all patients (if not 
contraindicated e.g. visual disturbances). This is based on clinical data showing a 
reduced occurrence of nonrenal and renal flares, diminished organ damage and 
better  survival in patients with SLE treated with antimalarial drugs(32). Screening 
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with an ophthalmologist for retinopathy at baseline and yearly after 5 years is advised 
(30).  
 Renin-angiotensin-aldosterone system (RAAS) inhibition for proteinuria and blood 
pressure control (target blood pressure <130/80)  
 Low dose acetylsalicylic acid in patients with antiphospholipid syndrome 
 Anticoagulation in those with albumin of less than 20g/l. 
 Tuberculosis prophylaxis with isoniazid ( for those in high endemic areas)  
 Contraception is necessitated for all patients on Mycophenolate Mofetil (MMF) or 
Cyclophosphamide (CYC), and pregnancy must be avoided until remission is sustained 
for a minimum of six months.  
 
4.2 Immunosuppressive treatment of lupus nephritis 
The therapeutic approach to lupus nephritis consist of 2 phases: induction and maintenance. 
The aim of induction is to promptly control kidney inflammation, reduce residual scarring and 
conserve renal mass. Therapeutic options have extended from the use of single 
corticosteroids to the addition of wide variety of chemotherapeutic drugs and other 
adjunctive treatment. In a systematic review and meta-analysis by Singh et al. there was 
significant difference in the effectiveness of corticosteroids (CS) and immunosuppressive 
drugs. Substantially lower risk of end stage renal disease (ESRD) was seen in the CYC and CYC 
+ azathioprine (AZA)  group compared with the CS only, [OR: 0.18 to 0.48] (33). 
The routine use of IVCYC in addition to glucocorticoids for the treatment of LN began after 
the ground breaking NIH trial(16). Since the 1980s, corticosteroids plus cyclophosphamide 
has been standard therapy for proliferative LN, clinical trials showed that cyclophosphamide 
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and corticosteroids was more efficient than corticosteroids alone in sustaining disease 
remission and preventing ESRD(34)(35)(36). The adverse events associated with  CYC 
(including leukopenia, alopecia, susceptibility to infections, gonadal toxicity, haemorrhagic 
cystitis, uroepithelial tumors and increased occurrence of other malignancies) have led to 
approaches that lessened cyclophosphamide exposure(16)(37). 
The Euro- Lupus Nephritis trial compared high- dose and low dose intravenous CYC, the results 
showed similar rates of improvement in serum creatinine, proteinuria, disease activity score 
and similar failure rates; interestingly both groups had no significant differences in the 
incidence of adverse effects(16). However, 76 of the 90 participants in the trial were 
Caucasians-who had mild to moderate severity of LN, and the Euro-Lupus regimen is usually 
not adopted in black patients, who frequently have severe disease that might not respond 
well to standard therapy and data for effectiveness of this regimen is lacking(38)(39)(40). 
The Aspreva Lupus management study (ALMS) trial compared the efficacy of MMF and IV CYC 
as induction therapy. For the induction phase, 370 patient with III, IV or V lupus nephritis were 
randomly assigned to treatment with corticosteroids plus either monthly intravenous 
cyclophosphamide (0.5- 1.0g/m2) or MMF ( 2.5-3.0g/day). The primary outcome was the 
proportion of patients who responded to treatment after 24 weeks. The results were not  
remarkably different between the two 2 groups, complete remission rates were comparable 
in both groups, achieved by 8.6% of the patients in the MMF group and 8.1% of the CYC group 
after 6 months. The response rates were comparable in Asian and Caucasian patients, the 
response rates were superior with MMF than cyclophosphamide in black patients(41). 
Current induction protocols utilize high dose corticosteroids with either IVCYC or MMF. The 
maintenance phase uses either MMF or azathioprine with low dose corticosteroids to 
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augment responses and avoid disease flares. Many trials have been conducted in the past 40 
years resulting in the publication of six guidelines in 2012 on the management of lupus 
nephritis(9)(42)(43)(44)(45)(46). Patients with proliferative LN should be pulsed with steroids 
and commenced on CYC or MMF as part of induction treatment. This is then ensued by 
maintenance treatment with MMF or Azathioprine with low doses of steroid(11)(23). At 
present there is no agreement on the duration of maintenance therapy. In South Africa the 
resolution to withdraw maintenance immunosuppression should be guided by sustained 
complete clinical response of at least 2 years(11). 
In South Africa the modified National Institute of Health regimen (NIH) is used for induction, 
it involves the use of 3 consecutive pulse doses of intravenous(IV) methylprednisolone (500-
750mg daily) together with immunosuppressive agent: CYC 0.5 -1g/m2 monthly for 6 months  
or MMF of 2-3g per day(11). The lifetime cumulative CYC exposure should not exceed 
36g(9).IV methylprednisolone is followed by prednisone (1mg/kg/day) tapered over 6 to 12 
months depending on the clinical response(11). 
 
Table 4:  KDIGO guidelines on management of lupus nephritis: ( reference) 
Class I- Minimal- mesangial LN 
              Treatment as dictated by the extrarenal clinical manifestations. 
Class II- mesangial-proliferative LN 
               Proteinuria <1g/dl as dictated by the extrarenal manifestations 
               Proteinuria >3g/dl be treated with corticosteroids or CNIs 
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Class III- Focal LN and Class IV Diffuse LN 
 
 Induction therapy: - corticosteroids combined with either MMF or cyclophosphamide, worsening LN( 
rising serum creatinine, worsening proteinuria) during the first three months of treatment, a change 
can be made to an alternative recommended initial therapy or a kidney biopsy is performed. 
 
Maintenance therapy: after induction therapy is complete, patients with class III and IV LN receive 
maintenance with low dose corticosteroids and azathioprine or MMF. 
Class V- Membranous LN 
  
Patients with normal kidney function and non-nephrotic range proteinuria should be treated with 
antiproteinuric and antihypertensive agents. 
Persistent nephrotic proteinuria should be treated with corticosteroids plus additional 
immunosuppressive agents CYC, MMF, CNI or Azathioprine. 
Class VI- Advanced sclerosis 
 
Treatment with corticosteroids and immunosuppressive agents only as dictated by the extrarenal 
manifestations of lupus. 
 
The oral CYC regimen is not a preferred  suggestion due to its associated  prolonged treatment 
duration, greater cumulative doses and additional serious leukopenia. When oral CYC is given, 
the dose is 2.0 to 2.5 mg/kg daily(47). IVCYC based induction regimen is extensively used in 
Africa and is supported by various guidelines(30), particularly for patients with proliferative 
lupus nephritis. Cyclophosphamide is cheaper and widely available in Africa than MMF, 
although few African countries have shown data on its usage. Recent availability of MMF 
generic formulations has led to lowered cost and increased usage in South Africa(23).  
4.3 Clinical course of lupus nephritis  
Significant innovations in early diagnosis, classification and chemotherapy  for patients with 
LN have resulted in a substantial improvement in renal and patient survival(48). Despite this 
improvement in survival, SLE patients with LN have poorer outcomes than those without renal  
involvement, signifying that LN is an exhibition of a more severe form of SLE(17).  
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The mortality rate from SLE is high in South Africa – the 5 year survival of 226 patients with 
SLE that were followed up for 55 months showed estimated survival rates between 57% and 
72%; infections, nephritis, neuropsychiatric diseases and hypocomplementia were coupled 
with increased  mortality, but multivariate analysis indicated nephritis as the key 
prognosticator of mortality(14).  
The predictors of poor outcomes in lupus nephritis has been studied in several cohorts and 
the following are shown to be associated with poor outcomes(49)(50)(38)(51)(52): 
 Systemic hypertension 
 Raised serum creatinine at the onset of LN 
 Diffuse proliferative glomerulonephritis (WHO –class IV) 
 Failure of remission in the first year following lupus therapy 
 Interstitial inflammation 
 Massive proteinuria 
 Black /Hispanic race 
 
A South African  study conducted by Ayodele et al showed that on multivariate analysis 
baseline creatinine, hypertension and failure to attain complete remission at  initial  
treatment were substantial predictors of development of chronic kidney disease in lupus 
nephritis patients(49). 
 
5.0 Gaps in literature 
There is evidence that MMF may be equally effective as CYC for induction. The ALMS trial 
found similar response rates for MMF and CYC (56.2% vs 53%; p =0.58). However, response 
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rates in the ALMS, in a group labelled “other” (mainly patients of African descent and mixed 
race), was notably higher in the MMF group (60.4% vs 38.5%; p= 0.033). This could imply 
better response to MMF in blacks and Hispanics(53). There are few African studies that have 
shown data with MMF use and LN outcomes mainly due to the cost or unavailability of 
MMF(23). 
Treatment of LN in Africa is challenged by lack of and very expensive chemotherapeutic 
agents, and by the lack of laboratory monitoring of patients. There are few published studies 
of patients with LN in Africa. An IVCYC- based induction regimen is commonly used, the high 
cost of MMF has limited its availability(22)(23). Recent accessibility of generic formulations of 
MMF in South Africa has led to reduced cost and increased usage for patients with LN, 
however data comparing the efficacy and outcomes of MMF and IVCYC are still not available.  
 
6.0 Motivation of the study  
The motivation to carry out this study is borne from the absence of data in Africa comparing 
the efficacy and outcome of patients treated with MMF or IVCYC during induction therapy for 
proliferative LN.  
Hence, the primary aim of this study is to assess treatment response (after induction therapy 
with MMF or CYC) in patients with proliferative LN (class III, IV, V+III and V+IV). 
Secondary objectives of this study will include; 
- To compare the adverse effects of treatment between both groups 
- To compare the rate of relapse post induction therapy between both groups 
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ABSTRACT  
Background: Lupus nephritis (LN) is a common manifestation of systemic lupus 
erythematosus (SLE) and is associated with end-stage renal disease, need for renal 
replacement therapy and death. There is no African data comparing the efficacy or outcome 
of patients managed with Mycophenolate mofetil (MMF) or intravenous (IV)  
cyclophosphamide (CYC) during induction of proliferative LN.  
Objectives: The study aimed to assess treatment response after induction therapy with MMF 
or IV CYC in patients with proliferative LN at a single centre in South Africa. 
Methods: We performed a retrospective review of records of patients with biopsy proven 
proliferative LN diagnosed and treated with either MMF or IV CYC at Groote Schuur Hospital 
(GSH), Cape Town, South Africa. We assessed remission status, adverse events and death 
between the two groups. 
Results:  Patients treated with IVCYC and MMF had a mean age of 30.3 ± 11.2 and 27.0 ± 6.9 
years respectively, (p=0.23). At baseline, the IVCYC group had significantly higher mean 
arterial pressure, serum creatinine and glomerular crescents (p<0.05). After completion of 
induction therapy, there was no significant difference in remission status (76.0% vs 87.5%, 
p=0.33) or relapse status (8.1% vs 10.3%; p=0.22) for the IVCYC and MMF groups, respectively. 
There was no significant difference in occurrence of infective complications IVCYC 20(30.8%) 
vs MMF 3(15.7%) p=0.20 or mortality IVCYC 14(21.5%) vs MMF 1(5.4%) p=0.17 between both 
groups. Estimated GFR at baseline was the only predictor of death (1.0 [0.9 – 1.0]; p=0.001).  
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Conclusion: Our study shows similar outcomes following induction treatment with MMF or 
IVCYC in patients with biopsy proven proliferative LN in South Africa. However, a prospective 
and randomized study is needed to adequately compare these outcomes. 
Word Count: 274 
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INTRODUCTION  
Systemic lupus erythematosus (SLE) is a chronic multi-system autoimmune disorder with a 
predilection for young females(1). The involvement of the kidneys or lupus nephritis (LN) is a 
major cause of morbidity and mortality in SLE patients since up to 60% of adults with SLE 
develop LN (2). In South Africa, presence of LN was the only factor associated with mortality 
in 226 SLE patients, with a 5-year survival rate of 60%(3). 
 Management of LN requires a timely and coordinated use of immunosuppressive therapy, 
which consists of induction and maintenance phases.  One of the goals of the management 
of LN is to achieve the best possible clinical efficacy with renal remission and minimal toxic 
effects from immunosuppressive agents. The treatment is dictated by the class of the disease 
and degree of activity and chronicity indices(4). Use of aggressive immunosuppressive 
therapy has improved the prognosis of SLE patients, but up to 5-20% still progress to end-
stage renal disease (ESRD) within ten years following the diagnosis of LN(5)(6). The 
progression to renal failure in patients with LN is higher in patients of African-American 
descent(7). Clinical trials indicated that the combination of Cyclopshosphamide(CYC) with 
steroids was more efficacious in sustaining disease quiescence and improving renal outcomes 
than corticosteroids alone; however there were concerns of adverse effects with CYC. 
(8)(9)(10).  
The demand for therapies which are less toxic with equal or better efficacy has motivated 
studies for novel medications. Several randomized controlled trials (RCT) comparing 
Mycophenolate Mofetil (MMF) and CYC as induction agents in LN have shown that MMF is as 
effective as cyclophosphamide and may offer some advantages with regards to lowered 
adverse events (11)(12)(13)(14). Given the high cost of MMF over CYC in Africa, very few 
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studies have shown report on MMF use for LN in Africans(15). The recent availability of 
generic formulations of MMF has led to reduced cost and increased usage in patients with LN 
in African settings.  We assessed response following induction therapy in patients with 
proliferative LN diagnosed and treated with MMF or IVCYC at a single centre in South Africa. 
METHODS  
Study population 
This study had a retrospective design and was carried out at the Division of Nephrology and 
Hypertension, Groote Schuur Hospital (GSH), Cape Town, South Africa. GSH is a tertiary 
hospital in Cape Town, Western Cape. The study included all patients with biopsy-proven 
proliferative LN and who received induction treatment with either IVCYC or MMF from 
January 2010 to December 2014 at the Division of Nephrology and Hypertension, GSH, and 
University of Cape Town. 
Patients included in the study were patients with biopsy-confirmed proliferative lupus 
Nephritis (class III, IV, V mixed type) classified according to the ISN/RPS 2003 criteria(16). The 




We collected relevant data including demographic, clinical (e.g. blood pressure, use of ACE-
inhibitors, induction with IVCYC or MMF), biochemical (serum creatinine, estimated 
glomerular filtration rate, urine protein-creatinine ratio, autoimmune biomarkers) and 
histological features of included patients. The estimated glomerular filtration rate was 
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calculated using the abbreviated Modification of Diets in Renal Disease (MDRD)(17). These 
data were recorded at time of biopsy, at 6 months, 12 months and at time of last follow-up 
visit. Information from biopsy reports including number of glomeruli, presence of interstitial 
fibrosis, number of crescents if present, and histology class were extracted. The side effects 
during treatment and any episodes of infection were recorded. 
Variable measurement 
Treatment response was measured by assessment of proteinuria and serum creatinine at 
regular intervals. Response to therapy in LN was assessed as complete response (CR), partial 
response (PR) or no response, ESRD, or death. Occurrence of these outcomes were measured 
at time of last follow up visit. Outcome measures were defined as per the Kidney Disease 
Improving Global Outcomes guidelines (KDIGO) as follows(18): 
- Complete remission (CR): Return of serum creatinine to the previous baseline, plus a 
decline in the urinary protein to creatinine ratio (uPCR) to < 0.5g/24 hours 
- Partial remission (PR): stabilisation (25%) or improvement of serum creatinine, but not 
to normal, plus a > 50% decrease in uPCR. If there was nephrotic range proteinuria 
(uPCR> 0.3g/24 hours), the improvement required a 50% reduction in the uPCR. 
- Deterioration was defined as a sustained 25% increase in the serum creatinine. 
- Relapse was defined as clinical manifestations indicating activity, namely, active 
urinary sediments, increasing proteinuria with or without serological reactivation in a 
patient who was previously in complete or partial remission 
Statistical analysis 
Statistical analysis was performed using Stata 15.1 (Stata Corp, TX, USA). The Student t-test 
was used to compare means between the two groups if normally distributed while the Mann-
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Whitney U test was used for comparison in cases of deviation from normality. The Chi-square 
was used for the statistical comparison of proportions between the two groups. Univariable 
and multivariable logistic regression models were used to identify independent associations 
with remission. Kaplan-Meier graphs were used to show the time-to-mortality experience of 
different groups within the cohort with the log-rank test used to compare survival experiences 
statistically. Cox proportional hazard models were used to identify independent predictors of 
mortality in the cohort. All differences in baseline characteristics between the two study 




Eighty-four patients with proliferative LN were included in the analysis. Overall, the mean age 
was 29.6±10.4 years with a female preponderance (88.1%). There was also a preponderance 
of patients of mixed ancestry (67.8%) but there was no significant difference in racial 
distribution of patients (p=0.86). Although mean systolic and diastolic blood pressures were 
higher in those treated with IVCYC than in those treated with MMF, only the mean arterial 
pressure was noted to be significantly higher in the IVCYC group (P=0.04) (Table 1). Other 
baseline features (for the groups and overall) are shown in Table 1. Overall, the median 
estimated glomerular filtration rate (eGFR) was noted to be 69.7 (IQR: 33.5 – 99.2 
ml/min/1.73m); this was significantly lower in the IVCYC group (p=0.02). (Table 1). 
Histological features and complications of treatment: 
Overall, there was a median of 14 (10–18) glomeruli per biopsy taken. The IVCYC group had a 
significantly higher proportion of crescents than the MMF group (3.8 [0.0 – 32.4] vs 0.0 [0.0 – 
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6.2]; p = 0.03). Presence of sclerosed glomeruli or any degree of interstitial fibrosis was not 
significantly different between the groups.  
Although infections (upper respiratory tract and urinary tract infections) occurred more 
frequently in the IVCYC group, there was no significant difference for infections between both 
treatment groups (p=0.20) (Table 2). Other complications that were reported including 
steroid induced diabetes and tuberculosis were also more frequent in the IVCYC group, but 
were not significantly higher than in the MMF group.  
Remission and Relapse  
At six months follow up, overall, remission (either complete or partial) occurred in 52 (78.8%, 
95% CI: 67.0-87.9%) patients with no significant difference between both treatment groups, 
p=0.33 (Table 3). The relapse rate at 12 months of therapy was also not significantly different 
between both groups; p=0.22 (Table 3). No independent predictor of remission emerged to 
be statistically significant from multivariable analysis (Table 4).   
Mortality  
A total of 15 deaths were reported; most (14/15) were in the IVCYC group (Table 2). The 
median time to death was 105 days (IQR 45-267 days) from the date of biopsy. During a total 
of 32,159 person-days of follow up, the mortality rate for the CYC group was 5.5 per 10,000 
person-days of follow up compared to 1.5 per 10,000 person-days of follow up for the MMF 
group. Figure 1 shows overall survival and survival between the two treatment groups. In all, 
no significant difference in mortality was found in any of the comparison pairs. Multivariable 
Cox-proportional hazards model showed eGFR at baseline as the only independent predictor 
of mortality in this group of patients (Table 5). For every 1 ml/min/1.73m2 increase in eGFR 
at baseline there was a 5% reduced risk of mortality in this cohort.  
 





An unmet need in the treatment of patients with LN in Africa is finding cheap and potent 
chemotherapeutic agents with minimal adverse effects. Combination IVCYC and high dose 
steroids have remained the cornerstone of treatment of LN in Africans leading to various side 
effects including infections, metabolic derangements and death(15)(19) (20).  Minimal data 
exists  on the spectrum, treatment, and outcome of LN in sub-Saharan Africa(21). We report 
a retrospective comparison of MMF and IVCYC in patients with proliferative LN treated in a 
single Centre in Cape Town, South Africa. The important findings from our study include: (i) 
after 6 months of induction therapy with either IVCYC or MMF, there was no difference in the 
proportion of patients attaining complete or partial remission between both groups, (ii) there 
was no significant difference in reported infections-related adverse events between both 
groups at the last follow-up visit and (iii) there was no significant difference in mortality 
between the two treatment groups (p 0.11). 
 
The Aspreva Lupus Management study (ALMS) was the first international RCT to compare the 
efficacy and safety of MMF with IVCYC for the induction therapy of patients with confirmed 
LN(22).  In the ALMS study, 370 patients with classes III through V LN were randomized to 
open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0g/m2 in monthly pulses) in a 24-wk 
induction study. Both groups received prednisone, tapered from a maximum starting dosage 
of 60 mg/d. The primary end point was a prespecified decrease in UPCR and stabilization or 
improvement in serum creatinine. Secondary end points included complete renal remission, 
systemic disease activity and damage, and safety. Overall, there was no significantly different 
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response rate between the two groups: [MMF - 56.2% vs IVCYC - 53.0%; p = 0.58]. Secondary 
end points were also reported to be similar between both treatment groups(22). Further 
analysis of the trial results however, showed that in patients with “other” as racial group 
(mainly Hispanics and African Americans), there was a significantly higher proportion of 
patients who responded to MMF (60.3% vs 38.5%; p = 0.033).  
Several studies comparing MMF and IVCYC for induction in patients with LN have since been 
published showing varied results but mainly that there is no difference in response rate 
between MMF and IVCYC treatments for induction(23)(24)(25)(26). A study from India 
randomized (equally) 100 patients to IVCYC or MMF for a 24 week induction treatment of 
LN(26). Baseline characteristics were similar between both groups; however, proteinuria was 
significantly higher  in the IVCYC group. At 24 weeks, the complete remission rate was 50% in 
CYC and 54% in MMF group (p=0.91)(26). Our study, conducted in a predominantly African 
population (black Africans and Africans with mixed ancestry) did not find any difference in 
response as the complete and partial remission rates were similar between the IVCYC and 
MMF groups. However, we are aware that this might be a sample size effect given a smaller 
sample size for the MMF group. 
The complications associated with treatment were infections (mainly upper respiratory and 
urinary tract types), pulmonary tuberculosis and steroid induced diabetes. Although our study 
did not find any significant difference in complications rate between both treatment groups, 
most occurred in the IVCYC group. This could be an indication of the severity of disease in this 
group (evidenced by lower eGFR at treatment initiation) or toxicity related to this treatment. 
For similar reasons, we also found higher mortality in the IVCYC group. Our findings are similar 
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to a study conducted by Thong et al. in which MMF was associated with lower infection risk 
than CYC in Non-Asians(14).  
Our study has a number of limitations. First, this was a retrospective analysis of those treated 
in a single centre in South Africa and therefore has all the biases associated with retrospective 
reviews including inadequate sampling and inability to adequately assess and document all 
adverse events as they occurred. Second, compliance to treatment was only certain in those 
who were receiving IVCYC as they had to come in to the clinic to receive the monthly pulse 
intravenous treatment. Compliance could, however, not be ascertained in the MMF group. 
Thus, what role this might have played regarding our results is not known. Also, given that 
lupus disease activity indices are not routinely checked in the Nephrology clinic, we were 
unable to obtain these scores which we could have correlated with response and relapse rates 
between both groups. Finally, the choice of induction therapy was solely based on physician 
preference given that those with more severe presentation, evidenced by significantly lower 
eGFR, were more likely to have been treated with IVCYC. Since it’s discovery, IVCYC has been 
the mainstay of therapy for LN (especially in Africa) given that it is readily available and cheap. 
The low use of MMF in our study is related to high cost. However, with availability of generic 
formulations and ability to monitor MMF levels in blood, it is expected that use of MMF will 
likely increase for the treatment of LN. Despite these limitations, our study is the first of its 
kind in South Africa where the prevalence of SLE (and LN) is highest amongst all sub-Saharan 
African countries. Therefore, our results provide evidence to clinicians for use of either MMF 
or IVCYC in treating patients with proliferative LN. We still recommend adequate monitoring 
of patients for infections and other side effects related to these therapies. 
 




CONCLUSION   
In South Africans with proliferative LN, our study has found no difference in response rate, 
relapse rate or occurrence of adverse effects to induction therapy with MMF or IVCYC. 
However, prospective studies to test our findings are still needed.  
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Figure 1: compares (a)shows overall survival and (b) survival between the IVCYC and MMF. In 
all, no significant difference in mortality was found in any of the comparison pairs. 
 
 














            Total24 
(N=84) 
p-value 
Mean age± SD (years)  30.3±11.2 27.0±6.9 29.6±10.4 0.23 
Female sex (%)  74.3 25.7 88.1 0.07 
Race (%) 
   Black  
   Coloured  















Mean SBP (at biopsy) (mmHg) 131.7±20.5 122.9±13.6 129.7±19.4 0.08 
Mean DBP at biopsy (mmHg)  80.1 (14.2) 73.2±10.7 78.5±13.7 0.05 
mABP (at biopsy) (mmHg)  97.4±15.0 89.7±10.9 95.7±14.5 0.04 
Use of ACE-I/ARB (%) 89.2 94.7 90.5 0.47 
Hb at biopsy (g/dl) 9.9±2.8 10.6±2.0 10.1±2.6 0.36 
WBC at biopsy (x109/L)  8.1±4.5 6.7±3.5 7.8±4.3 0.23 
Low C3 (%) 87.5 78.9 85.5 0.35 
Low C4  (%) 69.8 79.0 72.0 0.44 
Positive ANA (%) 86.9 88.9 87.3 0.82 
Positive dsDNA(%) 90.3 84.2 88.9 0.46 
Serum albumin (g/L)  28.2 ±6.9 29.5±9.59 28.5±7.5 0.51 
Median SCr (IQR) (µmol/L) 96 (65-192) 70 (58-84) 84.5 (62-174) 0.02 
Median eGFR (IQR) 
(ml/min/1.73m2) 
61.91 (27.9-94.5) 87.2 (69.6-106.8) 69.7(33.5-99.2) 0.02 
uPCR (mg/mmol) 320(185-585) 290(170-670) 310 (170-590) 0.92 
CYC=Cyclophosphamide; MMF=mycophenolate mofetil; SBP=systolic blood pressure; DBP=diastolic blood 
pressure; mABP=mean arterial blood pressure; ACE-I=angiotensin converting enzyme inhibitor ARB=angiotensin 
receptor blocker; Hb=haemoglobin; WBC=white blood cell count; ANA=anti-nuclear antibodies; dsDNA=double 
stranded DNA; SCr=serum creatinine; eGFR=estimated glomerular filtration rate; uPCR=urine protein-creatinine 
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Number of glomeruli (median) (IQR×) 13(9-16) 18(12-26) 14(10-18) 0.01 
Crescents %(IQR) 3.8(0.0-32.4) 0.0 (0.0-10.0) 0.0(0.0-28.6) 0.03 
%Sclerosed glomeruli(IQR) 0.0(0.0-5.5) 0.0(0.0-10.0) 0.0(0.0-5.5) 0.59 
Interstitial fibrosis n(%) 32(50.0) 7(36.8) 39(47.0) 0.31 
IgG deposits(n=82)     
0 15(23.8) 4(21.1) 19(23.2)  
1 12(19.1) 2(10.5) 14(17.1) 0.80 
2 23(36.5) 8(42.1) 31(37.8)  
3 13(20.6) 5(26.3) 18(21.9)  
IgM deposits     
0 11(17.6) 6(31.6) 17(20.7)  
1 13(20.6) 1(5.3) 14(17.1) 0.04 
2 24(38.1) 3(15.8) 2732.9)  
3 15(23.8) 9(47.4) 24(29.3)  
IgA deposits     
0 34(54.0) 10(52.6) 44(53.7)  
1 18(28.6) 2(10.5) 20(24.4) 0.21 
2 7(11.1) 4(21.1) 11(13.4)  
3 4(6.4) 3(15.8) 7(8.5)  
C3 deposits     
0 5(7.8) 2(10.5) 7(8.4)  
1 10(15.6) 4(21.1) 14(16.9) 0.61 
2 20(31.3) 3(15.8) 23(27.7)  
Complications (%) :     
Infection 20(30.8) 3(15.8) 23(27.3) 0.20 
Diabetes Mellitus 4(6.15) 0(0.0) 4(4.76) 0.57 
TB 2(3.1) 0(0.0) 2(2.4) 0.22 
Death 14(21.5) 1(5.3) 15(17.9) 0.17 
 
 CYC=Cyclophosphamide; MMF=mycophenolate mofetil  
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Table 3: Complete, partial remission and relapse in the two groups after therapy 
 
  CYC group  
(95%CI)  
MMF group  
(95%CI)  
Total  
(95% CI)  
P 
value 
CR at 6 months  18.0 (8.6-31.4)  25.0 (7.3-52.4)  19.7 (10.9-31.3)  0.54 
PR at 6 months  58.0 (43.2-71.8)  62.5 (35.4-84.8)  59.1 (46.3-71.0)  0.75 
CR + PR  76.0 (61.8-86.9)  87.5 (61.6-98.4)  78.8 (67.0-87.9)  0.33 
 
Relapse at 12 months  8.1 (1.7-21.9)  10.3 (4.3-48.1)  11.5 (4.3-23.4)  0.22 






Table 4: Predictors of Remission  
 
  Univariable models  
Odds ratio (95% CI)  
P value Multivariable model  
Odds ratio (95% CI)  
P value 
Induction regimen  
  Cyclophosphamide  
  Mycophenolate mofetil  
  
1  











   Female  
   Male  
  
1  










Age (years)  1.0 (0.9-1.1)  0.77 1.0 (0.9-1.1)  0.43 
Ethnicity  
   Black  
   Coloured  
  
1  










Baseline eGFR  1.0 (0.98-1.0)  0.85 1.0 (0.97-1.0)  0.43 
Baseline uPCR  1.0 (0.99-1.00)  0.45 1.0 (0.99-1.0)  0.26 
Interstitial fibrosis  1.0 (0.3-3.4)  0.95 1.7 (0.4-6.7)  0.46 
% Crescents  1.7 (0.1-20.4)  0.68 3.0 (0.1-68.2)  0.49 
% Sclerosed glomeruli  0.6 (0.0-9.4)  0.72 0.5 (0.0-14.6)  0.69 
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Table 5: Predictors of mortality 
Hazard ratio (95% CI) P value 
Treatment Regimen 
 CYC  
 MMF 
1 
0.07 (0.003-1.87) 0.11 





0.60 (0.06-5.87) 0.66 
Histology type 
 Non-proliferative 
 Proliferative  
1 





0.66 (0.14-3.01) 0.59 
eGFR at baseline  0.95 (0.92-0.98) 0.001 
uPCR at baseline  0.99 (0.99-1.00) 0.15 
Mean arterial blood pressure 0.97 (0.93-1.02) 0.15 
Interstitial fibrosis  0.34 (0.09-1.24) 0.10 
% Sclerosed glomeruli  0.99 (0.07-12.99) 0.99 
% Crescents   0.83 (0.08-8.37) 0.87 
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Q 1.  
Demographics  
 
Sex Race Age 
 
Q2. Biopsy  




















































    
 
Q 6. White cell 
count  






    
 
Q7. albumin  Albumin at Biopsy Albumin 6months Albumin 12months Albumin Last FU 












    
 
Q9. eGFR eGFR  at Biopsy eGFR 6months eGFR 12months eGFR Last FU 
    
 
Q10. U PCR U PCR   at Biopsy U PCR  6months U PCR  12months U PCR  Last FU 





C3 at Biopsy C4 at Biopsy  ANA at Biopsy Anti –Ds DNA at 
Biopsy 




Histology Class # of glomeruli  # of crescents  # of sclerosed 
glomeruli 
    
 
 Interstial  
fibrosis(Y/N)   
Ig A deposits Ig M  Ig G  C 3 
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CHLOROQUINE  SOLUMEDROL ORAL 
PREDNISOLONE 



















Prednisolone ( Y/ 
N ) 
Azathioprine ( 
Y/N )  
MMF ( Y/N )  CYCLOSPORINE ( 
Y / N ) 









Infections  TB  Diabetes  





(Y/ N )  
IF YES CAUSE OF DEATH  No Death  
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Guideline word limit: 4 000 words 
  
Research articles describe the background, methods, results and conclusions of an original 
research study. The article should contain the following sections: introduction, methods, 
results, discussion and conclusion, and should include a structured abstract (see below). The 
introduction should be concise – no more than three paragraphs – on the background to the 
research question, and must include references to other relevant published studies that 
clearly lay out the rationale for conducting the study. Some common reasons for conducting 
a study are: to fill a gap in the literature, a logical extension of previous work, or to answer 
an important clinical question. If other papers related to the same study have been 
published previously, please make sure to refer to them specifically. Describe the study 
methods in as much detail as possible so that others would be able to replicate the study 
should they need to. Results should describe the study sample as well as the findings from 
the study itself, but all interpretation of findings must be kept in the discussion section, 
which should consider primary outcomes first before any secondary or tertiary findings or 
post-hoc analyses. The conclusion should briefly summarise the main message of the paper 
and provide recommendations for further study. 
  
Select figures and tables for your paper carefully and sparingly. Use only those figures that 
provided added value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text. 
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Structured abstract 
 This should be 250-400 words, with the following recommended headings:
o Background: why the study is being done and how it relates to other published work.
o Objectives: what the study intends to find out
o Methods: must include study design, number of participants, description of the intervention,
primary and secondary outcomes, any specific analyses that were done on the data.
o Results: first sentence must be brief population and sample description; outline the results
according to the methods described. Primary outcomes must be described first, even if they
are not the most significant findings of the study.
o Conclusion: must be supported by the data, include recommendations for further
study/actions.
 Please ensure that the structured abstract is complete, accurate and clear and has been
approved by all authors.
 Do not include any references in the abstracts.
Main article 
All articles are to include the following main sections: Introduction/Background, Methods, 
Results, Discussion, and Conclusions. 
The following are additional heading or section options that may appear within these: 
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 Objectives (within Introduction/Background): a clear statement of the main aim of the study 
and the major hypothesis tested or research question posed 
 Design (within Methods): including factors such as prospective, randomisation, blinding, 
placebo control, case control, crossover, criterion standards for diagnostic tests, etc. 
 Setting (within Methods): level of care, e.g. primary, secondary, number of participating 
centres. 
 Participants (instead of patients or subjects; within Methods): numbers entering and 
completing the study, sex, age and any other biological, behavioural, social or cultural factors 
(e.g. smoking status, socioeconomic group, educational attainment, co-existing disease 
indicators, etc)that may have an impact on the study results. Clearly define how participants 
were enrolled, and describe selection and exclusion criteria. 
 Interventions (within Methods): what, how, when and for how long. Typically for randomised 
controlled trials, crossover trials, and before and after studies. 
 Main outcome measures (within Methods): those as planned in the protocol and those 
ultimately measured. Explain differences, if any. 
  
Results 
 Start with description of the population and sample. Include key characteristics of comparison 
groups. 
 Main results with (for quantitative studies) 95% confidence intervals and, where appropriate, 
the exact level of statistical significance and the number need to treat/harm. Whenever 
possible, state absolute rather than relative risks. 
 Do not replicate data in tables and in text. 
66 | P a g e  
 
 If presenting mean and standard deviations, specify this clearly. Our house style is to present 
this as follows: 
 E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for mean (SD). 
 Leave interpretation to the Discussion section. The Results section should just report the 
findings as per the Methods section. 
  
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-headings 
are not needed: 
 Statement of principal findings 
 Strengths and weaknesses of the study 
 Contribution to the body of knowledge 
 Strengths and weaknesses in relation to other studies 
 The meaning of the study – e.g. what this study means to clinicians and policymakers 
 Unanswered questions and recommendations for future research 
  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include primary 
conclusions and their implications, suggesting areas for further research if appropriate. Do 
not go beyond the data in the article. 
  
 
